| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8667591 | Journal of Arrhythmia | 2017 | 6 Pages |
Abstract
Atenolol is an effective treatment for genetically proven LQT1 and LQT2 children and adolescents, with good tolerability. In LQT1 patients, QTc intervals at 2-3Â min into the recovery phase of exercise were significantly prolonged, particularly in patients with transmembrane mutations.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Sit-Yee MB ChB, FHKCPaed, FHKAM, Andreas MD, FRACP, FCSANZ, CEPS, Sarah-Jane BSc (Hons), FHGSA, Erin MSc, Mangesh MD, Andrew Mark MBBS, MD, FRACP, FCSANZ, FHRS, CEPS,